Form 8-K - Current report:
SEC Accession No. 0001193125-25-230466
Filing Date
2025-10-03
Accepted
2025-10-03 17:24:23
Documents
22
Period of Report
2025-10-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d64736d8k.htm   iXBRL 8-K 43451
2 EX-1.1 d64736dex11.htm EX-1.1 235908
3 EX-1.2 d64736dex12.htm EX-1.2 201496
4 EX-5.1 d64736dex51.htm EX-5.1 23101
5 EX-5.2 d64736dex52.htm EX-5.2 11584
6 EX-5.3 d64736dex53.htm EX-5.3 13525
7 EX-5.4 d64736dex54.htm EX-5.4 6546
12 GRAPHIC g64736g1003120738049.jpg GRAPHIC 2952
13 GRAPHIC g64736g1003122257393.jpg GRAPHIC 2696
14 GRAPHIC g64736g32o38.jpg GRAPHIC 2978
  Complete submission text file 0001193125-25-230466.txt   858002

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA xoma-20251003.xsd EX-101.SCH 4580
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE xoma-20251003_def.xml EX-101.DEF 14449
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE xoma-20251003_lab.xml EX-101.LAB 24599
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE xoma-20251003_pre.xml EX-101.PRE 15482
25 EXTRACTED XBRL INSTANCE DOCUMENT d64736d8k_htm.xml XML 7796
Mailing Address 2200 POWELL STREET SUITE 310 EMERYVILLE CA 94608
Business Address 2200 POWELL STREET SUITE 310 EMERYVILLE CA 94608 510-204-7239
XOMA Royalty Corp (Filer) CIK: 0000791908 (see all company filings)

EIN.: 522154066 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39801 | Film No.: 251375036
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)